The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database

Abstract Background Lung cancer (LC) is a leading cause of cancer-related mortality worldwide. The combination of immune checkpoint inhibitors (ICIs) with chemotherapy significantly extends survival but increases the risk of treatment-related toxicity. To explore the impact of adding pembrolizumab t...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Shun Li, Zhifei Huang, Xiaoyu Zhong, Yan Zhou, Hao Jiang
Format: Article
Language:English
Published: BMC 2025-04-01
Subjects:
Immune checkpoint inhibitors
Pembrolizumab
Pemetrexed
Platinum
Cisplatin
Carboplatin
Online Access:https://doi.org/10.1186/s12885-025-14171-3

Internet

https://doi.org/10.1186/s12885-025-14171-3

Similar Items